Thinly traded nano cap Novus Therapeutics (NVUS +14.9%) is up on average volume following its updates on clinical trials supporting lead drug OP0201.
Phase 1 trials: first dose cohort completed in adult safety and tolerability study (C-002). Screening for second higher dose cohort underway. Initial screening underway in single-dose safety and pharmacodynamics study (C-001). Data from both trials should be available in Q2. Enrollment completed in single-dose safety and preliminary efficacy study (C-004) in adults with acute otitis media (ear infection) with data expected later this quarter.
A Phase 2a study, C-006, in infants and children with acute otitis media has been added. Enrollment will commence in the coming weeks with topline results expected in H2.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.